Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-05

Study Completion Date

2019-02-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open label randomised multicentre pre-surgical pharmacodynamics study to compare and assess the biological effects of AZD9496 and fulvestrant in postmenopausal women with estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor 2 (HER-2) negative (HER2-) primary breast cancer.

Patients will receive AZD9496 or fulvestrant and will have an on-treatment image

-guided core biopsy after 5-14 days of commencing treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

NCT01992952

Estrogen Receptor Positive Breast Cancer

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

NCT00454805

Advanced Breast Cancer

COMPLETED PHASE2

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

NCT00305448

Advanced Breast Cancer Metastatic Breast Cancer

COMPLETED PHASE2

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women

NCT01300351

Breast Cancer

COMPLETED PHASE3

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

NCT02374099

Breast Neoplasms

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label, randomized, multi-centre study in postmenopausal women with primary ER+ HER2- breast cancer. Patients will be randomised to an oral dose of 250 mg bd AZD9496 or 500mg fulvestrant i.m. administered on one occasion. Patients diagnosed with primary breast cancer who are scheduled for surgery with curative intent will be consented to the study including consent to use the formalin fixed paraffin embedded (FFPE) diagnostic tumor biopsy sample and fresh frozen tumor biopsy sample (if available) for research purposes. Patients may also consent to provide an optional pretreatment fresh frozen tumor biopsy sample if this was not obtained at the time of initial diagnostic biopsy. If the diagnostic biopsy was taken ≥ 6 weeks prior to starting treatment or was not of sufficient quality, new tumor core biopsies (FFPE and fresh frozen) must be taken. Following the screening visit, eligible patients will be randomised to receive one of the following study treatments:

* AZD9496 administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy OR
* fulvestrant 500 mg administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock.

After the morning dose of AZD9496 on the day of biopsy dosing will be stopped. If following initiation of AZD9496 treatment, dosing will be stopped if biopsy is postponed beyond Day 14. Patients will be considered not evaluable for the study if biopsy is postponed beyond day 14 of AZD9496/fulvestrant treatment initiation. Core tumor biopsies will be taken at either the time of definitive surgery or at a separate visit prior to surgery in the period between (and including) day 5 and day 14. Subjects who are scheduled to start a subsequent neoadjuvant therapy must have their core tumor biopsies performed before commencing neoadjuvant treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Not applicable, thisis an open-label study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard arm

Fulvestrant, 500 mg

Group Type ACTIVE_COMPARATOR

Standard Arm - Fulvestrant

Intervention Type DRUG

500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock

AZD9496

250 mg bd taken orally for 5-14 days

Group Type EXPERIMENTAL

AZD9496

Intervention Type DRUG

Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard Arm - Fulvestrant

500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock

Intervention Type DRUG

AZD9496

Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fulvestrant Study drug

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed and dated informed consent form (ICF)
2. Women \>=18 years
3. Patients with newly diagnosed resectable primary breast cancer scheduled to undergo treatment with curative intent by surgery
4. Histologically confirmed invasive breast cancer involving a palpable tumor of any size, or a tumor with an ultrasound assessed diameter of ≥ 1.0 cm
5. Any clinical nodal status
6. ER+breast cancer
7. HER2- breast cancer defined as a negative in situ hybridization test or an immno-histochemistry (IHC) status of 0 or 1+
8. Eastern Co-operative Oncology group (ECOG) performance status 0-1
9. Post-menopausal status defined as meeting at least one of the following criteria: Have undergone a bilateral oophorectomy; Age ≥60 years; Age ≥50 years and with cessation of regular menses ≥12 months and with an intact uterus in the absence of oral contraception or hormone-replacement therapy (HRT) prior to the diagnosis of breast cancer; Age \<60 years and with cessation of regular menses ≥12 months and follicle stimulating hormone (FSH) and oestradiol levels in the postmenopausal range

Exclusion Criteria

1. Pre-treatment biopsy sample not likely to provide adequate tissue sections for the biomarker assays
2. Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments)
3. Inflammatory breast cancer
4. Evidence of metastases
5. Patients currently receiving medications or herbal supplements known to be strong inhibitors/inducers of CYP3A4/5 or strong inhibitors of CYP2C8 or that are sensitive substrates of CYP2C8 inhibition
6. Concurrent treatment with other experimental drugs within 4 weeks prior to receiving study treatment
7. Use of hormone-replacement therapy from \<4 weeks of the diagnostic/baseline core biopsy to the start of trial treatment
8. Patients with second primary cancer. Any endocrine therapies or other anti-cancer therapies must have been ceased at least 12 months prior to enrollment.
9. Any of the following cardiac criteria:

* Mean resting QT interval corrected for heart rate (QTc) \> 470 msec obtained from 3 ECGs using Fridericia's formula
* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG
* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
10. Experience of any of the following in the preceding 6 months: coronary artery bypass graft (CABG), angioplasty, vascular stent, myocardial infarction (MI), angina pectoris, congestive heart failure New York Heart Association (NYHA) Grade ≥2, cerebrovascular accident (CVA), transient ischaemic attack (TIA), deep venous or arterial thrombosis, pulmonary embolism, bleeding diathesis (i.e., disseminated intravascular coagulation, clotting factor deficiency) or requirement of anticoagulant therapy
11. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases,
12. Uncontrolled symptomatic thyroid dysfunction (hyperthyroidism or hypothyroidism).
13. Unexplained symptomatic endometrial disorders.
14. Refractory nausea and vomiting, uncontrolled chronic GI diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9496.
15. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: absolute neutrophil count \< 1.5 x 109/L, Platelet count \< 100 x 109/L, Haemoglobin \< 90 g/L, alanine aminotransferase (ALT) \> 2.5x upper limit of normal (ULN), aspartate aminotransferase (AST) \> 2.5 x ULN, Total bilirubin \> 1.5 x ULN or \> 3 x in case of Gilbert's Syndrome, glomerular filtration rate \< 50 mL/min
16. Direct involvement in the planning and conduct of the study
17. History of hypersensitivity to AZD9496
18. History of hypersensitivity to fulvestrant and/or castor oil
19. Judgment by the investigator that the patient should not participate in the study if unlikely to comply with study procedures, restrictions and requirements In addition, the following is considered a criterion for exclusion from the exploratory genetic research: Previous allogeneic bone marrow transplant; Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection

Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No